medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2021, Number 4

<< Back Next >>

Acta Med 2021; 19 (4)

Acute over chronic hepatic insufficiency

Delgado AF, Ceballos VTBG, Curiel RJA, Díaz GEJ, Rodríguez WFL

Language: Spanish
References: 54
Page: 524-534
PDF size: 260.59 Kb.


ABSTRACT

There is a large population in Mexico with cirrhosis, which is among the first causes of death in our country. Patients with liver disease can be classified as compensated or decompensated, but there is a small portion of patients with liver disease to whom an insult added to their disease will lead them to a state of multiple organ failure, regardless of the reason for cirrhosis or its stage. This evolution that differs from those already known, is known as acute on chronic liver failure and is a newly described pathology. The importance of knowing this pathology is the prognosis and the management for the correct evolution of this type of patient. Materials and methods: A search was conducted on PubMed, Scholar Google, and the journal of Internal Medicine of Mexico, between 1995-2020. The main search terms were "cirrosis", OR "descompensación hepática", OR "insuficiencia hepática aguda sobre crónica", OR "síndrome hepatorrenal", OR "decompensated cirrhosis", OR "acute on chronic liver failure", OR "hepatorenal syndrome". Additional items were identified by internet research.


REFERENCES

  1. Soto-Estrada G, Moreno-Altamirano L, Pahua Díaz D. Panorama epidemiológico de México, principales causas de morbilidad y mortalidad. Rev Fac Med. 2016; 59 (6): 8-22.

  2. Cruces Girón RD, Galván Plata ME, Rangel Jiménez AM, Sandoval Mex AM. Diagnóstico y tratamiento de la insuficiencia hepática crónica. Evidencias y recomendaciones. CENETEC [Internet]. 2009; Available in: http://www.cenetec-difusion.com/CMGPC/IMSS-038-08/ER.pdf

  3. Rodríguez MA, Valencia RHS, Altamirano JT. Etiología y complicaciones de la cirrosis hepática en el Hospital Juárez de México. Rev del Hosp Juárez México [Internet]. 2008; 75 (4): 257-263. Disponible en: https://biblat.unam.mx/es/revista/revista-del-hospital-juarez-de-mexico/articulo/etiologia-y-complicaciones-de-la-cirrosis-hepatica-en-el-hospital-juarez-de-mexico

  4. Simonetto D, Asrani SK, Kamath PS. Zakim and Boyer's hepatology: a textbook of liver disease. 7th. Philadelphia: Elsevier; 2017, 324-332.e2.

  5. Gustot T, Moreau R. Acute-on-chronic liver failure vs. traditional acute decompensation of cirrhosis. J Hepatol [Internet]. 2018; 69 (6): 1384-1393. Available in: https://linkinghub.elsevier.com/retrieve/pii/S0168827818323705

  6. Escorsell MA, Mas OA. Acute on chronic liver failure. Gastroenterol Hepatol [Internet]. 2010; 33 (2): 126-134. Available in: https://linkinghub.elsevier.com/retrieve/pii/S0210570509005305

  7. Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G et al. Acute-on chronic liver failure. J Hepatol [Internet]. 2012; 57 (6): 1336-1348. Available in: https://linkinghub.elsevier.com/retrieve/pii/S0168827812005193

  8. Solé C, Solà E. Actualización en la insuficiencia hepática aguda sobre crónica. Gastroenterol Hepatol [Internet]. 2018; 41 (1): 43-53. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0210570517301358

  9. Sarin SK, Choudhury A, Sharma MK, Maiwall R, Al Mahtab M, Rahman S et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019; 13 (4): 353-390.

  10. Angeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee RP, Trebicka J et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol [Internet]. 2018; 69 (2): 406-460. Available in: https://linkinghub.elsevier.com/retrieve/pii/S0168827818319664

  11. Arroyo V, Moreau R, Kamath PS, Jalan R, Ginès P, Nevens F et al. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Prim [Internet]. 2016; 2 (1): 16041. Available in: http://www.nature.com/articles/nrdp201641

  12. Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RAFM. A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality. Liver Int [Internet]. 2013; 33 (1): 40-52. Available in: https://doi.org/10.1111/j.1478-3231.2012.02790.x

  13. O'Leary JG, Reddy KR, Garcia-Tsao G, Biggins SW, Wong F, Fallon MB et al. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology [Internet]. 2018; 67 (6): 2367-2374. Available from: http://doi.wiley.com/10.1002/hep.29773

  14. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology [Internet]. 2013; 144 (7): 1426-1437.e9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0016508513002916

  15. Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol [Internet]. 2014; 61 (5): 1038-1047. Available in: https://linkinghub.elsevier.com/retrieve/pii/S0168827814004085

  16. Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut [Internet]. 2017; 66 (3): 541-553. Available in: http://gut.bmj.com/lookup/doi/10.1136/gutjnl-2016-312670

  17. Alam A, Suen KC, Ma D. Acute-on-chronic liver failure: recent update. J Biomed Res [Internet]. 2017; 31 (4): 283-300. Available in: http://www.jbr-pub.org.cn/en/article/doi/10.7555/JBR.30.20160060

  18. Choudhury A, Kumar M, Sharma BC, Maiwall R, Pamecha V, Moreau R et al. Systemic inflammatory response syndrome in acute-on-chronic liver failure: Relevance of "golden window": A prospective study. J Gastroenterol Hepatol [Internet]. 2017; 32 (12): 1989-1997. Available in: http://doi.wiley.com/10.1111/jgh.13799

  19. D'Amico G, Morabito A, D'Amico M, Pasta L, Malizia G, Rebora P et al. New concepts on the clinical course and stratification of compensated and decompensated cirrhosis. Hepatol Int [Internet]. 2018; 12 (S1): 34-43. Available in: http://link.springer.com/10.1007/s12072-017-9808-z

  20. Nanchal R, Subramanian R, Karvellas CJ, Hollenberg SM, Peppard WJ, Singbartl K et al. Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU. Crit Care Med [Internet]. 2020; 48 (3): e173-191. Available in: http://journals.lww.com/10.1097/CCM.0000000000004192

  21. Xiao LL, Xu XW, Huang KZ, Zhao YL, Zhang LJ, Li LJ. Artificial liver support system improves short-term outcomes of patients with hbv-associated acute-on-chronic liver failure: a propensity score analysis. BioMed Res Int [Internet]. 2019; 2019: 1-8. Available in: https://www.hindawi.com/journals/bmri/2019/3757149/

  22. Sarin SK, Choudhury A. Management of acute-on-chronic liver failure: an algorithmic approach. Hepatol Int [Internet]. 2018; 12 (5): 402-416. Available from: http://link.springer.com/10.1007/s12072-018-9887-5

  23. Arroyo V, Jalan R. Acute-on-chronic liver failure: definition, diagnosis, and clinical characteristics. Semin Liver Dis [Internet]. 2016; 36 (02): 109-116. Available in: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0036-1583202

  24. Jalan R. Novel approaches and therapeutics in acute-on-chronic liver failure. Liver Transplant [Internet]. 2016; 22 (S1): 14-19. Available in: http://doi.wiley.com/10.1002/lt.24621

  25. Choudhury AK, Sharma MK, Maiwal R, Jain P, Mahtab MA, Chawla YK et al. The decision for liver transplant in acute on chronic liver failure (ACLF) - first week is the crucial period - analysis of the apasl ACLF research consortium (AARC) prospective data of 1021 patients. J Hepatol [Internet]. 2016; 64 (2): S151-152. Available in: https://linkinghub.elsevier.com/retrieve/pii/S0168827816000465

  26. Shen Y, Wang XL, Wang B, Shao JG, Liu YM, Qin Y et al. Survival benefits with artificial liver support system for acute-on-chronic liver failure. Medicine (Baltimore) [Internet]. 2016; 95 (3): e2506. Available in: http://journals.lww.com/00005792-201601190-00030

  27. Choudhury A, Jindal A, Maiwall R, Sharma MK, Sharma BC, Pamecha V et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. Hepatol Int [Internet]. 2017; 11 (5): 46-471. Available in: http://link.springer.com/10.1007/s12072-017-9816-z

  28. Lei J, Zeng Y, Xu L, Wang Y. Analysis of treatment of 3 patients with acute-on-chronic liver failure. Case Rep Med [Internet]. 2018; 2018: 1-4. Available from: https://www.hindawi.com/journals/crim/2018/7421502/

  29. Garg V, Garg H, Khan A, Trehanpati N, Kumar A, Sharma BC et al. Granulocyte colony-stimulating factor mobilizes CD34+ cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2012; 142 (3): 505-512.e1.

  30. Kedarisetty CK, Anand L, Bhardwaj A, Bhadoria AS, Kumar G, Vyas AK et al. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis. Gastroenterology. 2015; 148 (7): 1362-1370.e7.

  31. Duan X-Z. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol [Internet]. 2013; 19 (7): 1104-1110. Available from: http://www.wjgnet.com/1007-9327/full/v19/i7/1104.htm

  32. Angeli P, Ginès P, Wong F, Bernardi M, Boyer TD, Gerbes A et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. J Hepatol [Internet]. 2015; 62 (4): 968-974. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0168827814009581

  33. Davenport A, Sheikh MF, Lamb E, Agarwal B, Jalan R. Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit? Kidney Int [Internet]. 2017; 92 (5): 1058-1070. Available in: https://linkinghub.elsevier.com/retrieve/pii/S008525381730474X

  34. Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Prim [Internet]. 2018; 4 (1): 23. Available in: http://www.nature.com/articles/s41572-018-0022-7

  35. Wadei H, Gonwa T. Hepatorenal syndrome and other liver-related kidney disease. In: Weiner D. National Kidney Foundation's primer on kidney diseases. 7th ed. Philadelphia: Elsevier; 2018. 290-298.

  36. Tejeda-Maldonado J, Niño-Cruz JA, Cruz-Rivera C, Torre A, Aguirre-Valadez J. Evaluation of the royal free hospital cirrhosis glomerular filtration rate formula in hispanic patients with cirrhosis: an external validation. Rev Investig Clin [Internet]. 2019; 71: 195-203. Available in: http://www.clinicalandtranslationalinvestigation.com/frame_esp.php?id=219

  37. Torre A, Aguirre-Valadez JM, Arreola-Guerra JM, García-Flores OR, García-Juárez I, Cruz-Rivera C et al. Creatinine versus cystatin C for estimating GFR in patients with liver cirrhosis. Am J Kidney Dis [Internet]. 2016; 67 (2): 342-344. Available in: https://linkinghub.elsevier.com/retrieve/pii/S0272638615012536

  38. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology [Internet]. 2008; 134 (5): 1360-1368. Available from: https://linkinghub.elsevier.com/retrieve/pii/S001650850800245X

  39. Nassar Junior AP, Farias AQ, D'Albuquerque LA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. Bruns H, editor. PLoS One [Internet]. 2014; 9 (9): e107466. Available in: http://dx.plos.org/10.1371/journal.pone.0107466

  40. Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology [Internet]. 2015; 62 (2): 567-574. Available in: http://doi.wiley.com/10.1002/hep.27709

  41. Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology [Internet]. 2016; 63 (3): 983-992. Available from: http://doi.wiley.com/10.1002/hep.28396

  42. Wijdicks EFM, Longo DL, editor. Hepatic encephalopathy. N Engl J Med [Internet]. 2016; 375 (17): 1660-1670. Available in: http://www.nejm.org/doi/10.1056/NEJMra1600561

  43. Khoury T, Ayman AR, Cohen J, Daher S, Shmuel C, Mizrahi M. The complex role of anticoagulation in cirrhosis: an updated review of where we are and where we are going. Digestion [Internet]. 2016; 93 (2): 149-159. Available in: https://www.karger.com/DOI/10.1159/000442877

  44. Kurokawa T, Ohkohchi N. Platelets in liver disease, cancer and regeneration. World J Gastroenterol [Internet]. 2017; 23 (18): 3228-3239. Available in: https://pubmed.ncbi.nlm.nih.gov/28566882

  45. Cheloff AZ, Al-Samkari H. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med [Internet]. 2019; 10: 313-321. Available in: https://pubmed.ncbi.nlm.nih.gov/31565009

  46. Abdela J. Current advance in thrombopoietin receptor agonists in the management of thrombocytopenia associated with chronic liver disease: focus on avatrombopag. Clin Med Insights Blood Disord [Internet]. 2019; 12: 1179545X19875105-1179545X19875105. Available in: https://pubmed.ncbi.nlm.nih.gov/31673229

  47. Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med [Internet]. 2012; 367 (8): 716-724. Available in: https://doi.org/10.1056/NEJMoa1110709

  48. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M et al. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ [Internet]. 2013; 346: f839. Available in: http://www.bmj.com/cgi/doi/10.1136/bmj.f839

  49. Moeller C, Fleischmann C, Thomas-Rueddel D, Vlasakov V, Rochwerg B, Theurer P et al. How safe is gelatin? A systematic review and meta-analysis of gelatin-containing plasma expanders vs crystalloids and albumin. J Crit Care [Internet]. 2016; 35: 75-83. Available in: https://linkinghub.elsevier.com/retrieve/pii/S0883944116300375

  50. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M et al. Albumin Replacement in Patients with Severe Sepsis or Septic Shock. N Engl J Med [Internet]. 2014; 370 (15): 1412-1421. Available in: http://www.nejm.org/doi/10.1056/NEJMoa1305727

  51. Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology [Internet]. 2015; 62 (1): 243-252. Available from: http://doi.wiley.com/10.1002/hep.27849

  52. Staufer K, Roedl K, Kivaranovic D, Drolz A, Horvatits T, Rasoul-Rockenschaub S et al. Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications. Liver Int [Internet]. 2017; 37 (6): 843-850. Available in: http://doi.wiley.com/10.1111/liv.13389

  53. Levesque E, Saliba F, Ichai P, Samuel D. Outcome of patients with cirrhosis requiring mechanical ventilation in ICU. J Hepatol [Internet]. 2014; 60 (3): 570-578. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0168827813008131

  54. Karvellas CJ, Pink F, McPhail M, Austin M, Auzinger G, Bernal W et al. Bacteremia, Acute Physiology and chronic health evaluation II and modified end stage liver disease are independent predictors of mortality in critically ill nontransplanted patients with acute on chronic liver failure. Crit Care Med [Internet]. 2010; 38 (1): 121-126. Available in: http://journals.lww.com/00003246-201001000-00019




2020     |     www.medigraphic.com